探索特发性肺纤维化的病理机制：研究进展与挑战

园园 崔(济宁市第一人民医院，中国)

摘要

特发性肺纤维化(IPF)是一种病因未明的慢性、进行性间质性肺疾病，病理特征为肺实质内弥漫性炎症反应与胶原异常沉积导致的肺结构破坏及纤维化，属于间质性肺疾病范畴。好发于50岁以上人群，男性发病率稍高于女性，临床预后不良，患者平均生存时间在3至5年之间。其发病率曾逐年增高趋势，发病原因不明，病情多进展迅速，临床无特效治疗药物，给患者及家属造成严重的身心伤害。关于其发病机制，众说纷纭，但主要集中在氧化应激、上皮-间质转化、细胞信号传导通路等几个方面，本文就肺间质纤维化发病机制进行论述总结。

关键词

特发性肺间质纤维化；氧化应激反应；上皮细胞向间质转化；细胞信号转导途径

参考

Cameli, P, Carleo, A, Bergantini, L, et al. Oxidant/Antioxidant Disequilibrium in Idiopathic Pulmonary Fibrosis Pathogenesis. INFLAMMATION. 2020; 43 (1): 1-7. doi: 10.1007/s10753-019-01059-1.

Lv, M, Liu, Y, Ma, S, et al. Current advances in idiopathic pulmonary fibrosis: the pathogenesis, therapeutic strategies and candidate molecules. FUTURE MED CHEM. 2019; 11 (19): 2595-2620. doi: 10.4155/fmc-2019-0111.

Muramatsu, Y, Sugino, K, Ishida, F, et al. Effect of inhaled N-acetylcysteine monotherapy on lung function and redox balance in idiopathic pulmonary fibrosis. RESPIR INVESTIG. 2015; 54 (3): 170-8. doi: 10.1016/j.resinv.2015.11.004.

Gao, L, Jiang, D, Geng, J, et al. Hydrogen inhalation attenuated bleomycin-induced pulmonary fibrosis by inhibiting transforming growth factor-β1 and relevant oxidative stress and epithelial-to-mesenchymal transition. EXP PHYSIOL. 2019; 104 (12): 1942-1951. doi: 10.1113/EP088028.

Lv, N, Huang, C, Huang, H, et al. Overexpression of Glutathione S-Transferases in Human Diseases: Drug Targets and Therapeutic Implications. Antioxidants (Basel). 2023; 12 (11): doi: 10.3390/antiox12111970.

Liu, W, Han, X, Li, Q, et al. Iguratimod ameliorates bleomycin-induced pulmonary fibrosis by inhibiting the EMT process and NLRP3 inflammasome activation. BIOMED PHARMACOTHER. 2022; 153 113460. doi: 10.1016/j.biopha.2022.113460.

Bastos, VAF, Fujimura, PT, Souza, AG, et al. Activin A Inhibitory Peptides Suppress Fibrotic Pathways by Targeting Epithelial-Mesenchymal Transition and Fibroblast-Myofibroblast Transformation in Idiopathic Pulmonary Fibrosis. Int J Mol Sci. 2025; 26 (6): doi: 10.3390/ijms26062705.

Li, K, Liu, H, Li, M, et al. Mechanistic insights into the treatment of pulmonary fibrosis with bioactive components from traditional chinese medicine via matrix stiffness-mediated EMT. Phytomedicine. 2024; 136 156266. doi: 10.1016/j.phymed.2024.156266.

Park, SJ, Kim, TH, Lee, K, et al. Kurarinone Attenuates BLM-Induced Pulmonary Fibrosis via Inhibiting TGF-βSignaling Pathways. Int J Mol Sci. 2021; 22 (16): doi: 10.3390/ijms22168388.

Lv, Q, Wang, J, Xu, C, et al. Pirfenidone alleviates pulmonary fibrosis in vitro and in vivo through regulating Wnt/GSK-3β/β-catenin and TGF-β1/Smad2/3 signaling pathways. MOL MED. 2020; 26 (1): 49. doi: 10.1186/s10020-020-00173-3.

Huang, K, Zhang, Q, Ruan, H, et al. Pazopanib attenuated bleomycin-induced pulmonary fibrosis via suppressing TGF-β1 signaling pathway. J THORAC DIS. 2024; 16 (4): 2244-2258. doi: 10.21037/jtd-23-1349.

Chen, Y, Yin, H, Sun, J, et al. TrxR/Trx inhibitor butaselen ameliorates pulmonary fibrosis by suppressing NF-κB/TGF-β1/Smads signaling. BIOMED PHARMACOTHER. 2023; 169 115822. doi: 10.1016/j.biopha.2023.115822.

Simon, AR, Rai, U, Fanburg, BL, et al. Activation of the JAK-STAT pathway by reactive oxygen species. AM J PHYSIOL. 1998; 275 (6): C1640-52. doi: 10.1152/ajpcell.1998.275.6.C1640.

Severgnini, M, Takahashi, S, Rozo, LM, et al. Activation of the STAT pathway in acute lung injury. AM J PHYSIOL-LUNG C. 2004; 286 (6): L1282-92. doi: 10.1152/ajplung.00349.2003.

Xiao, T, Ren, S, Bao, J, et al. Vorapaxar proven to be a promising candidate for pulmonary fibrosis by intervening in the PAR1/JAK2/STAT1/3 signaling pathway-an experimental in vitro and vivo study. EUR J PHARMACOL. 2023; 943 175438. doi: 10.1016/j.ejphar.2022.175438.

DOI: http://dx.doi.org/10.12345/yzlcyxzz.v8i8.30659